Table. Baseline characteristics of the study population with CKD Stages 3a-3b-4 according missing data in KFRE's predicted risk

|  | **Imputed Data** **(% col)** | **Available Data** **(% col)** | **Complete data in all variables used for multiple imputation** **(% row)** | | |
| --- | --- | --- | --- | --- | --- |
| **Characteristic** | **N = 30,031** | **N = 30,031** | **All variable with complete data**  N = 9,818 | **At least 1 variable with missing data**  N = 20,213 | **p-value** |
| **Sex** |  |  |  |  | <0.0011 |
| Femenino | 13,097 (43.6%) | 13,097 (43.6%) | 2,591 (19.8%) | 10,506 (80.2%) |  |
| Masculino | 16,934 (56.4%) | 16,934 (56.4%) | 7,227 (42.7%) | 9,707 (57.3%) |  |
| **Age (years)** |  |  |  |  | <0.0012 |
| Mean (SD) | 73.8 (11.1) | 73.8 (11.1) | 75.6 (11.6) | 73.0 (10.8) |  |
| Median (Q1 - Q3) | 75.0 (67.0 - 82.0) | 75.0 (67.0 - 82.0) | 76.0 (69.0 - 84.0) | 74.0 (66.0 - 81.0) |  |
| Min - Max | 18.0 - 109.0 | 18.0 - 109.0 | 18.0 - 109.0 | 22.0 - 108.0 |  |
| **EsSalud Network** |  |  |  |  | <0.0011 |
| Metropolitan Lima | 14,784 (49.2%) | 14,784 (49.2%) | 8,897 (60.2%) | 5,887 (39.8%) |  |
| Other Regions | 15,247 (50.8%) | 15,247 (50.8%) | 921 (6.0%) | 14,326 (94.0%) |  |
| **Hypertension** |  |  |  |  | <0.0011 |
| No | 7,254 (24.2%) | 6,620 (27.2%) | 325 (4.9%) | 6,295 (95.1%) |  |
| Yes | 22,777 (75.8%) | 17,696 (72.8%) | 4,736 (26.8%) | 12,960 (73.2%) |  |
| Missing |  | 5,715 | 4,757 | 958 |  |
| **Diabetes Mellitus** |  |  |  |  | <0.0011 |
| No | 17,567 (58.5%) | 13,643 (63.7%) | 746 (5.5%) | 12,897 (94.5%) |  |
| Yes | 12,464 (41.5%) | 7,782 (36.3%) | 2,231 (28.7%) | 5,551 (71.3%) |  |
| Missing |  | 8,606 | 6,841 | 1,765 |  |
| **Persistent Albuminuria Categories** |  |  |  |  |  |
| A1 | 14,662 (48.8%) | 5,183 (52.8%) | 5,183 (100.0%) | 0 (0.0%) |  |
| A2 | 10,095 (33.6%) | 2,874 (29.3%) | 2,874 (100.0%) | 0 (0.0%) |  |
| A3 | 5,274 (17.6%) | 1,761 (17.9%) | 1,761 (100.0%) | 0 (0.0%) |  |
| Missing |  | 20,213 | 0 | 20,213 |  |
| **eGFR Categories** |  |  |  |  | <0.0011 |
| G3a | 18,491 (61.6%) | 18,491 (61.6%) | 5,043 (27.3%) | 13,448 (72.7%) |  |
| G3b | 8,201 (27.3%) | 8,201 (27.3%) | 3,423 (41.7%) | 4,778 (58.3%) |  |
| G4 | 3,339 (11.1%) | 3,339 (11.1%) | 1,352 (40.5%) | 1,987 (59.5%) |  |
| **CKD KDIGO Classification** |  |  |  |  |  |
| Low risk | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) |  |
| Moderately increased risk | 9,403 (31.3%) | 3,106 (31.6%) | 3,106 (100.0%) | 0 (0.0%) |  |
| High risk | 10,169 (33.9%) | 3,102 (31.6%) | 3,102 (100.0%) | 0 (0.0%) |  |
| Very high risk | 10,459 (34.8%) | 3,610 (36.8%) | 3,610 (100.0%) | 0 (0.0%) |  |
| Missing |  | 20,213 | 0 | 20,213 |  |
| **Serum Creatinine (mg/dL)** |  |  |  |  | <0.0012 |
| Mean (SD) | 1.4 (0.4) | 1.4 (0.4) | 1.5 (0.4) | 1.4 (0.4) |  |
| Median (Q1 - Q3) | 1.3 (1.2 - 1.6) | 1.3 (1.2 - 1.6) | 1.4 (1.3 - 1.7) | 1.3 (1.1 - 1.5) |  |
| Min - Max | 0.9 - 4.5 | 0.9 - 4.5 | 0.9 - 4.1 | 0.9 - 4.5 |  |
| **eGFR using CKD-EPI (ml/min/1.73m²)** |  |  |  |  | <0.0012 |
| Mean (SD) | 45.9 (10.8) | 45.9 (10.8) | 43.2 (10.4) | 47.2 (10.8) |  |
| Median (Q1 - Q3) | 48.5 (39.4 - 54.5) | 48.5 (39.4 - 54.5) | 45.4 (36.5 - 51.3) | 50.1 (41.3 - 55.7) |  |
| Min - Max | 15.0 - 60.0 | 15.0 - 60.0 | 15.0 - 60.0 | 15.0 - 60.0 |  |
| **Albumin-Creatinine Ratio (mg/g)** |  |  |  |  |  |
| Mean (SD) | 802.1 (3,534.1) | 984.5 (4,075.4) | 984.5 (4,075.4) | NA (NA) |  |
| Median (Q1 - Q3) | 32.0 (8.1 - 160.3) | 25.5 (5.8 - 155.1) | 25.5 (5.8 - 155.1) | NA (NA - NA) |  |
| Min - Max | 0.6 - 27,817.5 | 0.6 - 27,817.5 | 0.6 - 27,817.5 | Inf - -Inf |  |
| Missing |  | 20,213 | 0 | 20,213 |  |
| **Urine Albumin (mg/dl)** |  |  |  |  | 0.0342 |
| Mean (SD) | 35.8 (161.5) | 56.5 (212.8) | 56.5 (212.9) | 58.3 (210.3) |  |
| Median (Q1 - Q3) | 1.6 (0.4 - 8.4) | 1.7 (0.4 - 11.5) | 1.7 (0.4 - 11.5) | 2.9 (0.7 - 16.0) |  |
| Min - Max | 0.0 - 1,365.2 | 0.0 - 1,365.2 | 0.0 - 1,365.2 | 0.0 - 1,365.2 |  |
| Missing |  | 21,249 | 1,186 | 20,063 |  |
| **Urine Creatinine (mg/dL)** |  |  |  |  | <0.0012 |
| Mean (SD) | 60.8 (50.5) | 65.9 (45.0) | 76.5 (42.7) | 46.4 (42.6) |  |
| Median (Q1 - Q3) | 49.2 (27.0 - 85.0) | 58.3 (36.7 - 85.0) | 69.6 (45.7 - 91.4) | 40.9 (10.6 - 64.9) |  |
| Min - Max | 0.1 - 221.3 | 0.1 - 221.3 | 0.1 - 221.3 | 0.1 - 221.3 |  |
| Missing |  | 16,739 | 1,187 | 15,552 |  |
| **2-Year Mortality** |  |  |  |  | <0.0011 |
| No | 27,640 (92.0%) | 27,640 (92.0%) | 8,801 (31.8%) | 18,839 (68.2%) |  |
| Yes | 2,391 (8.0%) | 2,391 (8.0%) | 1,017 (42.5%) | 1,374 (57.5%) |  |
| **2-Year Outcome** |  |  |  |  | <0.0011 |
| Alive w/o Kidney Failure | 27,227 (90.7%) | 27,227 (90.7%) | 8,661 (31.8%) | 18,566 (68.2%) |  |
| Kidney Failure | 793 (2.6%) | 793 (2.6%) | 348 (43.9%) | 445 (56.1%) |  |
| Death w/o Kidney Failure | 2,011 (6.7%) | 2,011 (6.7%) | 809 (40.2%) | 1,202 (59.8%) |  |
| **5-Year Mortality** |  |  |  |  | <0.0011 |
| No | 24,261 (80.8%) | 24,261 (80.8%) | 7,480 (30.8%) | 16,781 (69.2%) |  |
| Yes | 5,770 (19.2%) | 5,770 (19.2%) | 2,338 (40.5%) | 3,432 (59.5%) |  |
| **5-Year Outcome** |  |  |  |  | <0.0011 |
| Alive w/o Kidney Failure | 23,579 (78.5%) | 23,579 (78.5%) | 7,236 (30.7%) | 16,343 (69.3%) |  |
| Kidney Failure | 1,308 (4.4%) | 1,308 (4.4%) | 574 (43.9%) | 734 (56.1%) |  |
| Death w/o Kidney Failure | 5,144 (17.1%) | 5,144 (17.1%) | 2,008 (39.0%) | 3,136 (61.0%) |  |
| 1Pearson's Chi-squared test | | | | | |
| 2Wilcoxon rank sum test | | | | | |